Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Canagliflozin versus Perindopril on central blood pressure and carotid-femoral pulse wave velocity in type 2 diabetes and hyperetnsion patients pretreated with amlodipine

Next Previous
Trial Profile

Effects of Canagliflozin versus Perindopril on central blood pressure and carotid-femoral pulse wave velocity in type 2 diabetes and hyperetnsion patients pretreated with amlodipine

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary) ; Perindopril (Primary)
  • Indications Essential hypertension; Type 2 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 14 Apr 2021 Results assessing effect of canagliflozin and perindopril on serum uric acid, blood pressure and carotid femoral pulse wave velocity in Diabetic patients with hypertension, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.
  • 29 Jul 2018 New trial record
  • 11 Jun 2018 Results presented at the 28th European Meeting on Hypertension and Cardiovascular Protection

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top